Multiplexing of PCR Assays in Breast Cancer Analysis
Zusammenfassung
Leseprobe
Inhaltsverzeichnis
Table of Contents
1 Introduction
1.1 Breast Cancer
1.2 RNA Expression Profiling and Prediction
1.3 Conceptional Formulation and Objectives
2 Materials and Methods
2.1 Materials
2.1.1 Instruments and Consumables
2.1.2 Buffers and Chemicals for Nucleic Acid Purification
2.1.3 Nucleic Acids, Cell Lines and Tissue Samples
2.1.4 Synthetic Oligonucleotides
2.1.5 Chemicals and Kits for PCR
2.1.6 Software
2.2 Methods
2.2.1 General Approach
2.2.2 Purification of Nucleic Acids
2.2.3 Creation of a Standard Reference RNA Pool
2.2.4 Real-Time Kinetic RT-PCR
2.2.5 Designing Dually Labeled Primer-Probe Sets
2.2.6 Dilution of Primer-Probe Sets
2.2.7 Setup of Singleplex kPCR Assays
2.2.8 Evaluation of Different Reporter Dyes
2.2.9 Controlling of Primer-Probe-Set Performance
2.2.10 Testing Combinations of Two Sets (Duplexing)
2.2.11 Testing Combinations of Three Sets (Triplexing)
3 Results
3.1 Identification of Suitable Reporter Dyes
3.2 Evaluation of Primer-Probe-Performance
3.3 Identification of Suitable Duplex Combinations
3.4 Identification of Suitable Triplex Combinations
4 Discussion
4.1 Statistical Evaluation of Primer Performances
4.1.1 Slope
4.1.2 Efficiency
4.1.3 Y-Intercept
4.2 Suitable Reporter Dyes and Quencher
4.3 Optimization of Assays and kinetic RT-PCR Parameter
5 Summary
6 Literature
7 Appendix
7.1 Abbreviations
7.2 Figures
7.3 Tables
7.4 Oligonucleotide Sequences
7.5 Origins of Breast Cancer Samples for MAVPOOL080623a
7.6 Acknowledgements
1 Introduction
1.1 Breast Cancer
“Cancer” describes a group of various diseases, where cells start changing their molecular structure and begin to grow and to supersede normal cells. Cancer is induced by numerous different elicitors, which finally all lead to an interference of the genetically regulated balance between cell cycle and apoptosis. Although every organ in the human body can be afflicted with cancer, there are significant differences in frequency relating amongst others to age, sex, geographic region and personal habits.
In the industrialized countries, breast cancer is the leading cause of death for women at the age between 30 and 60 years. With estimated 636.000 incident cases in the developed countries and 514.000 in the developing countries, breast cancer is the most prevalent cancer type among woman worldwide [World Cancer Report 2008].
Once detected, the cancer is classified based upon pathological characterizations of the tumor or a biopsy and the lymph nodes. A clinical way of characterizing the tumor is the TNM-classification, which describes the size of the tumor (T), the number of affected lymph nodes (N) and the existence of distant metastases (M). The histological classification characterizes the carcinoma according to its structural and cellular appearance and the amitosis rate leading to a grading from 1 to 3. An immuno-histological examination provides information about the estrogen- and the progesterone-receptor- and about the Her-2/neu-status [Wolff A et al 2007].
Breast cancer is a very heterogeneous disease. There are basic classifications that are unquestioned, even today. Recent studies confirmed the need to determine well known markers (i.e. estrogen (ER) and progesterone (PR) receptor status [Garcia-Closas M, 2008] or HER2 status [Science Daily, 2007]), but the large variety of subtypes and the corresponding different molecular pattern impede a uniform treatment.
Although already today other factors than anatomical classifications are being taken into consideration, there exists a need for further biological markers to assist the physician in charge with his evaluation. Beside the diagnostic recognition, the choice of appropriate therapy and the prediction of prognosis are goals that should be reached in order to prevent early stage cancer patients from therapies that provide minimal benefit but reduce their quality of life by intense adverse reactions [Ganz PA et al 2004].
1.2 RNA Expression Profiling and Prediction
Already today there are numerous genes associated with breast cancer occurrence, therapy selection and prognosis [van ‘t Veer LJ et al 2002]. These profiles can be generated by different techniques, like DNA-microarrays or kinetic polymerase chain reaction (kPCR). The kPCR displays the handier platform for research laboratories in terms of choices of genes. It was the method of choice during this work.
Besides choosing the appropriate genes for analysis, there are several other elementary requirements that may lead to solid results like a statistical relevant number of tissue samples and a dependable and accurate follow-up documentation of the patient’s disease history. Within this follow-up, clinical parameters and important events like the recurrence of tumors, discovery of metastasis or demise must be documented. These parameters can then be correlated to gene expression profiles by extensive statistical analysis [Buyse M et al 2007].
Targeting patients with lymph-node-negative breast cancer, Siemens Healthcare Diagnostics designed a diagnostic assay to predict the probability of developing distant metastasis after surgery within 5 to 10 years. This kPCR-based quantification method draws upon several previously determined and selected genes, and uses formalin-fixed, paraffin-embedded (FFPE) tissue samples of 310 patients from the Department of Obstetrics and Gynecology, Johannes-Gutenberg-University Mainz, Germany [Stropp U et al 2008]. After quantifying these genes of interest (GOI) and normalizing on housekeeping genes (HKG), the determined amounts were correlated with comprehensive statistical data of the patients. Finally an algorithm was developed to predict the forecast of patients and to determine their need for chemotherapy.
This diagnostic assay consists of 9 GOIs, 2 HKGs and 1 DNA control and is performed within a 96-well polypropylene plate.
To verify suitable algorithms, they have to be confirmed within control groups. 7 different algorithms were developed by in-house statisticians, who applied different mathematical approaches. These 7 algorithms were then applied to control groups to determine the most reliable and reproducible method.
1.3 Objectives
The goal of this work was to reduce the amounts of wells per patient and assay by transforming the existing 12 singleplex assays into duplex- and triplex-formats, in order to increase the number of samples per plate or to allow more reference-control genes within a multiplex assay.
The primary goals of this project are:
- Reduction of cost of approximately 50% for mastermixes per patient
- Higher throughput due to larger sample number per plate
- Larger number and higher variety of GOIs per patient and plate
- Retrenchment of very valuable RNA material
- Generation of resources to run additional quality assurance (housekeeping-genes)
The platform the kPCRs were performed on was Stratagene’s MX3005p – a multichannel kPCR machine which possesses a tungsten halogen lamp and 5 different filter sets for parallel analysis of the corresponding amount of reporter dyes. It is able to excite and detect fluorophores with an excitation and emission wavelength between 400 and 700nm [Marras 2005]. The identification of suitable reporter dyes for the filter sets by performance-analysis was the initial requirement during this work, following the evaluation of compatibility of dyes among each other within multiplex assays. Finally the most promising and reliable multiplex assays had to be identified amongst the numerous different possible combinations.
In the context of this evaluation process great attention was put on consistent parameter during kPCR (i.e. buffer conditions, reaction volume, usage of identical lots, cycle conditions, etc.) and to strictly exclude any crosstalk between the individual channel.
The results emerging from this work will deliver a substantiated basis upon which further comparative studies with more comprehensive numbers of patients can be measured. Then, in-house bioinformaticians will test the existing algorithm on data gained from multiplex assays of a statistical larger universe of patients.
2 Materials and Methods
2.1 Materials
2.1.1 Instruments and Consumables
EPPENDORF, Hamburg, Germany
Centrifuge 5804, Cat. No.: 5804 000.013 with
Centrifuge Rotor A-2-DWP, Cat. 5804 740.009
Pipet Reference variable 0,1 – 2,5µl, Cat. No.: 4910 000.085
Pipet Reference variable 0,5 – 10µl, Cat. No.: 4910 000.018
Pipet Reference variable 10 – 100µl, Cat. No.: 4910 000.042
Pipet Reference variable 100 – 1000µl, Cat. No.: 4910 000.069
GILSON. Middleton, WI, USA
Repititive Pipet Distriman. Cat. No.: F164001
HEIDOLPH, Schwabach, Germany
Vortexer Reax Control, Cat. No.: 541-11000
LABNET, Woodbridge, NJ, USA
Centrifuge Quick Spin Minifuge, Cat. No.: C1201
SARSTEDT, Siegburg, Germany
Micro tube with screw cap 1.5ml, Cat. No.: 72.692.005
STRATAGENE, La Jolla, CA, USA
Mx3005P QPCR System, Cat. No.: 401458 with Alexa405-, ROX-, HEX-, FAM- and Cy5-Filter
Mx3000P®/Mx3005P® Optical Strip Caps, Cat. No.: 401425
Mx3000P® 96-well-plates skirted, Cat. No.: 401334
TECAN, Crailsheim, Germany
Robot Genesis Workstation 150
2.1.2 Buffers and Chemicals for Nucleic Acid Purification
QIAGEN, Hilden, Germany
Proteinase K, Cat. No.: 19133
SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBH, Eschborn, Germany
Lysis Buffer, Cat. No.: 03745099
Washing Buffer I, Cat. No.: 03745226
Washing Buffer II, Cat. No.: 03746737
Washing Buffer III, Cat. No.: 03742146
Elution Buffer, Cat. No.: 03742677
Magnetic Beads, Cat. No.: 03749787
2.1.3 Nucleic Acids, Cell Lines & Tissue Samples
DSMZ, Braunschweig, Germany
German Collection of Microorganisms and Cell Cultures, Braunschweig
MCF-7 cell line, Cat.No.: DSMZ ACC 115
(RNA isolated using QIAGEN, RNeasy Mini Kit, Cat.No. 74104 according to manufacturers instructions)
STRATAGENE, La Jolla, CA, USA
Stratagene QPCR Reference Total RNA, Human, Cat. No.: 750500
BREAST CANCER SAMPLES
Prof. Dr. med Stephan Störkel, Helios Klinikum Wuppertal, Departement for Pathology
Prof. Dr. Med Carsten Denkert, Charite Berlin, Departement for Pathology
Samples from women with invasive breast cancer, surgery 2003
5-10µm Slides of FFPE Samples with tumor cell content >30%
Informed Consent of Patients at hand.
2.1.4 Synthetic Oligonucleotides
MICROSYNTH, Balgach, Switzerland
HPLC-purified oligonucleotides and MALDI/TOF-controlled probes
(See appendix for complete listing of oligonucleotide sequences)
2.1.5 Chemicals and Kits for PCR
AMBION, Austin, TX, USA
Nuklease-free water (not DEPC-treated), Cat. No.: AM9932
RNaseZap, Cat. No.: AM9782
DNAzap, Cat. No.: AM9890
INVITROGEN, Carlsbad, CA, USA
SuperScript III Platinum One-Step qRT-PCR kit, Cat. No.: 11732-088
2.1.6 Software
MICROSOFT, Redmont, WA, USA
Microsoft Office Professional Edition 2003
APPLIED BIOSYSTEMS, Foster City, CA, USA
Primer Express Version 2.0.0
STRATAGENE, La Jolla, CA, USA
MxPro – Mx3005p v4.01 Build 369, Scheme 80
2.2 Methods
2.2.1 General Approach
All working steps concerning the handling of RNA were performed at a reserved working place and with instruments, which were kept RNAse free.
Unless otherwise noted, when water is mentioned in the text, nuclease-free water is referred to.
2.2.2 Purification of Nucleic Acids
Nucleic acids (NA) used in the context of this work were derived from formalin-fixed, paraffin embedded (FFPE) tissues of women with breast cancer surgery and from MCF-7 cell lines (see appendix 6.2). The tissue samples were available as paraffin sections of 5-10µm thickness and were stored at 8°C in 1,5ml Sarstedt reaction tubes. MCF-7 cell line is commercially available from the German Collection of Microorganisms and Cell Cultures, Braunschweig.
All nucleic acids extracted from patients breast-cancer samples were purified by an automated in-house sample preparation method using magnetic beads [Hennig G and Hildenbrand K 2006], specific solutions and a pipetting-robot (Figure 1).
Within this method, RNA was extracted from FFPE-samples. For this, samples were treated with a lysis buffer and Proteinase K and incubated for 2h at 65°C.
Together with a special binding buffer, the magnetic beads were added and incubated for another 10min at room temperature (RT).
While magnetizing the bead-bounded NAs, three wash-steps with washing buffer I - III removed waste compounds.
Finally an elution buffer was used to separate the NAs from the magnetic beads at 70°C and a DNAse I digestions removed the DNA to obtain the desired, pure RNA.
illustration not visible in this excerpt
Figure 1: Schematic Workflow of Nucleic Acid Extraction from FFPE Samples
2.2.3 Creation of a Standard Reference RNA Pool
A standard reference RNA pool was needed for further testings. Previous experiments had shown, that commercially available reference RNAs (i.e. Universal Human Reference RNA, Stratagene, Cat. No.: 740000) did not represent a realistic gene profile, since some genes of interest (GOI) are only amplified in patients RNA but not in commercial reference RNAs. (Mojica WD, Stein L, Hawthorn L 2008).
Therefore, RNA from 83 breast cancer samples and MCF-7 cells (see appendix for details of origin) was isolated and the extracted RNA was combined into a common pool. A dilution series was made by diluting the RNA with nuclease free water according to the following scheme:
Table 1: Dilution Series of Human Breast Cancer Samples for Setting up a Standard Reference RNA Pool
illustration not visible in this excerpt
5000µl of each dilution was then aliquoted in 50 x 100µl and stored as “MAVPOOL080623a” at -80°C.
2.2.4 Real-Time Kinetic RT-PCR
The real-time quantitative RT-PCR method used to quantify RNA in breast cancer tissue combines two successive steps.
First, RNA is transcribed into cDNA by the enzyme reverse transcriptase, an RNA-dependent DNA-polymerase, which was first discovered in retroviruses (Gilboa E et al 1979) and which is able to synthesize a RNA-DNA-hybrid-strand from a single-stranded RNA, degrade the residual RNA and complete the molecule into a double-stranded cDNA.
In the second step, the cDNA serves as a template for the following quantitative polymerase chain reaction (PCR). The PCR uses two sequence-specific oligonucleotides and a DNA-dependent polymerase to amplify a definite DNA segment (Mullis KB, Faloona FA 1987).
An improvement of the PCR is the real-time quantitative PCR, where a third oligonucleotide, a hybridization probe labeled with two different fluorescent dyes and located between the forward- and the reverse-primer, is used. Since one dye works as the reporter dye (i.e. FAM, Cy5, Yakima Yellow, etc.) and the other one as the corresponding quencher (like TAMRA, BHQ1, BHQ2, etc.), the quencher absorbs the emission of the reporter dye by fluorescent resonance energy transfer (FRET).
When this dual-labeled probe hybridizes with the template DNA, the 5’-3’ nucleolytic activity of the polymerase degrades this probe resulting in a loss of quenching activity. Thus, a continuous increase of occurs during PCR. The amount of fluorescence at a given time point during PCR corresponds to the amount of PCR product. Since fluorescence is measured following each PCR cycle, it is possible to observe the amplification process “real-time” and to count back to the initial amount of cDNA (Heid CA, Stevens J, Livak K J et al.1996).
2.2.5 Designing Dually Labeled Primer-Probe Sets
Primer design was accomplished with the help of the software tool Primer Express v2.0.0 from Applied Biosystems. Although this software was built for designing TaqMan® primer and probe sets, it delivers excellent results for other real-time applications such as the MX3005p. When choosing TaqMan® Primer and Probe Design, the software operates with predefined parameters using empirical rules to calculate optimal sequences based upon the input sequence. The most important parameters for the probe were:
- Amplicon size should range from 50 – 150 base pairs (bp)
- G/C content should be kept between 30% and 80%
- Avoiding repeats of identical bases – especially of Guanine
- The melting temperature should be between 68°C and 70°C
- No 5’-terminal Guanine
- Primers should be designed a close to the probe as possible
(Source: Primer Express Software Version 3.0 Getting Started Guide)
The corresponding forward- and reverse-primer were also automatically designed by that software and their melting temperature should have been about 10°C below the probe-temperature.
Although all samples were treated with DNAse, this digestion is very often imperfect [Wink, 2004]. The use of RNA-specific primer probe sets copes with that specific problem. In order to avoid amplification of genomic DNA, RNA-specific, intron-spanning [Freeman, 1999] primer-probe sets were designed if possible, based upon the cDNA sequence.
All primer-probe sets were ordered from Microsynth, Switzerland in 0.2µmol scale and HPLC purified.
2.2.6 Dilution of Primer-Probe Sets
Each set consisted of two standard oligonucleotides and one dual-labeled probe. Both, the unmodified and the modified oligonucleotides were first diluted to a final concentration of 100µM according to the documents provided by Microsynth. The working solution consisted of 50µl (each) forward and reverse primer and 25µl probe filled up with nuclease free water to a total volume of 1000µl. Thus, the working solution consisted of two unmodified oligonucleotides (5µM each) and one dual-labeled probe (2,5µM).
2.2.7 Setup of Singleplex kPCR Assays
The standard setup for a singleplex QPCR was based upon a total volume of 20µl. The following quantities of the constituents were used:
Table 2: Setup of a Standard kPCR Assay
illustration not visible in this excerpt
After combining mastermix, water, primer-probe mix and MgSO4, the RT/Taq mix and the RNA was added, whereas both, the RT/Taq mix and the RNA must be handled on wet ice and all pipetting steps were performed on wet ice, too.
MgSO4 might affect the performance of the PCR, since its concentration affects primer annealing, denaturation of the strands and product specifity. In addition, MgSO4 is needed for the activity of enzymes. Since primer and nucleotides capture available MgSO4 [Mülhardt, C., 2000] the concentration was elevated by adding 1µl of 50mM MgSO4 to the mix. Since the 2x mastermix already contains 6mM MgSO4 the final concentration is increased by 2.5mM to 5.5mM MgSO4 [Henegariu O et al 1997].
After diluting the primer-probe mix, the final concentrations per assay are 250nM for each of the two unmodified oligonucleotides and 125nM for the dual-labeled probe.
Reactions were performed in 96-well polypropylene plates. After pipetting all required components, the plate is sealed with lids and centrifuged at 1500rpm for 5min before transferring it to the Stratagene MX3005p QPCR machine. This step is useful to remove possibly existing bubbles on the ground of each well, resulting in better duplicates.
The thermal profile was set based upon Invitrogens recommendations regarding their SuperScript III Platinum One-Step Quantitative RT-PCR System protocol. An adjustment of 50 cycles instead of 40 was the only change that was carried out.
illustration not visible in this excerpt
Figure 2: Thermal Profile of RT-QPCR on the Stratagene Mx3005p
Figure 2 shows the thermal profile during a RT-QPCR run, starting with a 30min incubation time at 50°C at which the cDNA synthesis is performed by the reverse transcriptase. Following this step, the real-time PCR is run. An initial 95°C step for 2:00min is followed by 50 cycles with 20sec at 95°C [denaturation of template DNA] and 45sec at 60°C [hybridization of template DNA and synthetic oligonucleotides]. Fluorescence measurement and data collection was performed during the hybridization of PCR products at the end of each cycle.
2.2.8 Evaluation of Different Reporter Dyes
The real-time QPCR-System Mx3005p from Stratagene is equipped with 5 different filters, which allow detection of up to 5 different dyes in one single reaction. The instrument used in the context of this work features the following filters:
- Alexa Fluor 350 (350nm ex. – 440nm em.)
- FAM / SYBR Green I (492nm ex. – 516nm em.)
- HEX/JOE/VIC (535nm ex. – 555nm em.)
- ROX / Texas Red (585nm ex. – 610nm em.)
- Cy5 (635nm ex. – 665nm em.)
The Mx3005P system utilizes a quartz tungsten halogen bulb as its excitation light source. This bulb emits light from 350 to 750 nm (Stratagene, Strategies, 2005) and with that it is possible to test a large number of different dyes. The following different reporter dyes- and quencher-combinations were tested:
- FAM – BHQ1 (max Abs. 494nm – max. Em. 520nm)
- Yakima Yellow – BHQ1 (max Abs. 530nm – max. Em. 549nm)
- Cy5 – BHQ2 (max Abs. 646nm – max. Em. 662nm)
- Marina Blue – Dabcyl (max Abs. 362nm – max. Em. 459nm)
- Alexa 405 – Dabcyl (max Abs. 401nm – max. Em. 421nm)
- Pacific Blue – Dabcyl (max Abs. 416nm – max. Em. 451nm)
- ATTO620 – BHQ2 (max Abs. 619nm – max. Em. 643nm)
- HEX – BHQ1 (max Abs. 535nm – max. Em. 556nm)
- Alexa 350 – Dabcyl (max Abs. 346nm – max. Em. 442nm)
- ROX – BHQ2 (max Abs. 585nm – max. Em. 605 nm)
- ATTO550 – BHQ2 (max Abs. 554nm – max. Em. 576nm)
(Absorption and emission spectra derived from: Custom Oligonucleotides, Eurogentec, Belgium, 2007)
Before different dyes were tested for multiplexing, the compatibility with the Mx3005p QPCR machine and its filters had to be confirmed. For that purpose, all dyes had to pass an initial test, where they were tested on Stratagenes QPCR human Reference Total RNA and the in-house RNA pool “MAVPOOL080623a “. The test consisted of an amplification of a basic dilution series in which a broad spectrum of dilutions (1:1, 1:4, 1:16 and 1:64) was covered. Dyes, which were not detected by the system or produced very inconsistent results did not pass this initial test and were discarded.
2.2.9 Controlling of Primer-Probe-Set Performance
Before using new primer-probe sets in routine work, all sets undergo a process of testing their performance. Therefor each set is tested in the MAVPOOL080623a-dilution series and the performance is calculated (and, where applicable, compared to older charges).
Given dilutions (undiluted, 1:4, 1:16 and 1:64) and corresponding Ct-values make it possible, to calculate several parameters in Microsoft Excel:
- Slope calculated with the following formula:
=SLOPE(Ct-Values;LOG(dilutions))
- Efficiency calculated with the following formula:
=10^(-1/ slope)
- Efficiency (%) calculated with the following formula:
=(10^(-1/ slope)-1)*100
- Coeff Determination calculated with the following formula:
=RSQ(Ct-Values;LOG(dilutions))
- Y-Intersection calculated with the following formula:
=INTERCEPT(Ct-Values;LOG(dilutions))
For evaluation purposes, the efficiency (%) is the most common value used to determine the quality of new, or the comparability of re-ordered primer-probe sets. The performance of new primer-probe sets should be between 95% and 105% in best cases; still well acceptable efficiency ranges are between 90% and 110%. For re-ordered primer-probe sets, an approximate difference lower than 5% should be obtained. In any case, only measured values within the linear range may be used for calculations. Experiments have shown that the linear range covers Ct-values between 18 and approx. 35. Dyes, that did not pass this performance test, were discarded.
2.2.10 Testing Combinations of Two Primer-Probe Sets (Duplexing)
Primer-probe sets that passed both, the performance- and the initial dye test, were tested against each other to examine their performance in duplex reactions. The remaining dyes FAM, Cy5, Yakima Yellow and ROX showed persuasive results and possess distinguishable absorption- and emission spectra (Figure 3 & 4).
illustration not visible in this excerpt
Figure 3: Absorption Spectra of FAM (green), Yakima Yellow (orange), ROX (red) and Cy5 (blue), Source: http://www.biosearchtech.com/hot/multiplexing.asp
illustration not visible in this excerpt
Figure 4: Emission Spectra of FAM (green), Yakima Yellow (orange), ROX (red) and Cy5 (blue), Source: http://www.biosearchtech.com/hot/multiplexing.asp
Thus, primer-probe sets were tested systematically against each other, whereas the individual oligonucleotide concentration and the total reaction volume were retained, but the pursuant amount of water was decreased. However, every duplex testing plate also included wells containing the corresponding singleplex assays of the two individual primer-probe sets. By choosing a specific fluorescence channel (i.e. FAM in an assay containing one FAM-labeled and one Cy5-labeled probe) it was possible to make a comparable performance-analysis of this specific probe within the mixture of two probes and to compare the ascending slope with the slope of the parallel singleplex assay.
illustration not visible in this excerpt
Figure 5: Comparative Evaluation of GAPDH-FAM in Duplex Reactions with RACGAP1-Cy5 (marked magenta) and with RACGAP1-YY (marked yellow) versus the Corresponding Singleplex Reaction of GAPDH-FAM (marked blue).
A discrepancy of the PCR efficiency of approx. 10% or more lead to a negative weighting of that individual assay (marked red in Table 3). Irregularly shaped curves led to markings (marked yellow in Table 3), whereas in most cases the duplex reactions worked fine (marked green in Table 3).
2.2.11 Testing Combinations of Three Sets (Triplexing)
Primer-probe sets that passed the duplex-evaluation were tested for their triplex capability. Similar to the duplex-testing, three different reporter dyes were combined into a single assay. Again, the individual oligonucleotide concentration and the total reaction volume were retained, but the pursuant amount of water was decreased. Analysis of the performance was made by plotting the Ct-values against the RNA-concentration and comparing the slope of the singleplex-assay against the slope of the triplex-assay while examining one discrete channel.
To prevent influences on the Ct-values caused by crosstalk between different filter-channels, great importance was attached to the fact, that no fluorescence signals could be detected in wells, where a specific dye was not present. For example: A well containing FAM only must not produce values when analyzing this well with the Cy5- or the HEX-filter.
A third, even though somewhat imprecise attention was turned to the level of saturation. During duplex- and even more during triplex-assays, the individual reactions compete for the inserted components. It is therefore expected, that performance and saturation will deteriorate, but experiments have shown, that there are combinations, which show less influence than others. These combinations were favored for further testing.
3 Results
3.1 Identification of Suitable Reporter Dyes
The objective of this work was to combine singleplex kPCR assays of the following genes into multiplex assays:
Table 3: Overview of Tested Genes and Their Derivation
illustration not visible in this excerpt
All gene expression analysis performed within this work took place on Stratagenes MX3005p QPCR system. This system is equipped with 5 different filter sets, which make it possible to run multiplex analysis with up to 5 different reporter dyes.
To compare standard dyes that were recommended by Stratagene with none-proprietary alternative dyes, a set of four genes (TOP2A, RACGAP1, CHPT1 and IGKC) was chosen. Eleven different labeled sets per gene were then ordered to find the best dye that fits an individual filter setting.
To determine, whether a dye fits to a certain filter setting, a dilution series of Stratagenes QPCR human Reference Total RNA and the in-house RNA pool “MAVPOOL080623a “ was quantified in a 3-fold assay. The analysis of those assays focused on the issue, whether a dye is detectable or not. For this purpose, the appearance of amplification curves, their shape and the plausibility of an appearance was considered.
Experiments showed, that Alexa 405, Alexa 350 and ATTO620 did not show any detectable fluorescence at all and were therefore discarded. Analysis of raw data showed very high background fluorescence, which was initially interpreted as a non-effective dye-linking to the oligonucleotide. This suspicion was later confirmed by the oligo supplier who analyzed his samples.
Pacific Blue and Marina Blue dyes had to be discarded, although they showed detectable fluorescence, but their emittance spectrum was not discrete enough. Marina Blue, a reporter dye with an absorption maximum of 362nm and an emission maximum of 459nm should have been detectable with the Alexa 350 filter. In fact, this dye was detectable (figure 6) but also showed signals in the FAM-filter (figure 7) and was therefore not practicable for multiplexing.
illustration not visible in this excerpt
Figure 6: Fluorescence Signal of MLPH (marina blue labeled) in the Alexa 350 Filter Channel
illustration not visible in this excerpt
Figure 7: Fluorescence Signal of MLPH (marina blue labeled) in the FAM Filter Channel
The direct comparison of HEX-, Yakima Yellow- and ATTO550-labeled primer-probe-sets showed an advantage of ATTO550 over HEX. It was obvious, that HEX-labeled sets performed erratic over the different concentrations of the standard RNA concentration curve (Figure 8).
illustration not visible in this excerpt
Figure 8: Performance of 4 HEX-Labeled Primer-Probe-Sets on Standard-RNA-Dilution-Series
By taking the mean of the 3-fold determination and plotting the results against a logarithmic scale of RNA-concentrations, the advantages of ATTO550 became obvious.
illustration not visible in this excerpt
Figure 9: Performance of 4 ATTO550-labeled Primer-Probe-Sets on Standard-RNA-Dilution-Series
Since ATTO550 and Yakima Yellow both performed very well (Figure 9 and 10) but used the same MX3005p-filter set, only one of them could be used for further triplex testing.
illustration not visible in this excerpt
Figure 10: Performance of 3 Yakima Yellow-labeled Primer-Probe-Sets on Standard-RNA-Dilution-Series
The analysis of the tested efficiencies of both primer-probe sets showed, that ATTO550-labeled sets possess a significant lower efficiency than Yakima Yellow-dyes (Table 4). Further testing of ATTO550 was resigned at this point.
[...]
Details
- Seiten
- Erscheinungsform
- Erstausgabe
- Erscheinungsjahr
- 2009
- ISBN (PDF)
- 9783863416072
- ISBN (Paperback)
- 9783863411077
- Dateigröße
- 573 KB
- Sprache
- Englisch
- Institution / Hochschule
- Johannes Gutenberg-Universität Mainz
- Erscheinungsdatum
- 2012 (März)
- Note
- 1
- Schlagworte
- Breast Cancer PCR Polymerasekettenreaktion Brustkrebs Multiplex
- Produktsicherheit
- BACHELOR + MASTER Publishing